Primary T‐cell‐based delivery platform for in vivo synthesis of engineered proteins is a research paper published in Bioengineering & Translational Medicine (2023). On theSindex it has a DataRank of 0. It has been cited 3 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Defense Advanced Research Projects Agency
Grant: D19AP00024
Division of Cancer Prevention, National Cancer Institute
Grant: R21CA236640
Division of Cancer Prevention, National Cancer Institute
Grant: R33CA247739
NIH Office of the Director
Grant: DP2EB024245
National Institutes of Health
Grant: 1R33CA247739-01
T-cell Biofactories for targeting extracellular matrix
National Institutes of Health
Grant: 5R21CA236640-02
T-cell Biofactories for targeting interstitial fluid pressure
National Institutes of Health
Grant: 1DP2EB024245-01
Self-assembled therapeutics with spatiotemporal resolution
FWCI
0.35
Citation Percentile
0.6%
Citation Trend
Fields of Study
Keywords